| Identification | Back Directory | [Name]
BMS-585248 | [CAS]
619331-12-3 | [Synonyms]
BMS-585248
CIO2TZZ9H1
CHEMBL236995
UNII-CIO2TZZ9H1
1-(4-benzoylpiperazin-1-yl)-2-[4-fluoro-7-(triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione
1,2-Ethanedione, 1-(4-benzoyl-1-piperazinyl)-2-[4-fluoro-7-(1H-1,2,3-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]- | [Molecular Formula]
C22H18FN7O3 | [MDL Number]
MFCD28386230 | [MOL File]
619331-12-3.mol | [Molecular Weight]
447.42 |
| Hazard Information | Back Directory | [Uses]
BMS-585248 is a potent, third-generation HIV-1 attachment inhibitor with a promising initial in vitro and in vivo pharmacokinetic profile[1]. | [in vivo]
BMS-585248 (intravenous (1 mg/kg) and oral (5-200 mg/kg); once) has a good pharmacokinetic profile, with AUC values of 3220 nM·h and 8064 nM·h after IV (1 mg/kg) and oral (5 mg/kg) administration in male rats, respectively[1]. | Animal Model: | Male rats[1] | | Dosage: | 5, 15, and 200 mg/kg | | Administration: | Orally, once (Pharmacokinetic Analysis) | | Result: | Pharmacokinetic Parameters of BMS-585248 in male rats[1].
| PO | | | | Dose (mg/kg) | 15 | 75 | 200 | | Cmax (μM) | 6.6 | 8.4 | 11 | | AUCtot (μM·h) | 42 | 115 | 145 |
|
| [IC 50]
HIV-1 | [References]
[1] Regueiro-Ren A, et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment 13. Synthesis and profiling of a novel amminium prodrug of the HIV-1 attachment inhibitor BMS-585248. J Med Chem. 2013 Feb 28;56(4):1670-6. DOI:10.1021/jm301638a |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|